Key result
Blocking Oct3 or Golgi-resident β1ARs prevents norepinephrine-dependent cardiac myocyte hypertrophy via internal GPCRs.
Why the study?
Recent data demonstrated that GPCRs, including βARs, are activated intracellularly, but the biological significance remained unclear.
Does blockade of Golgi resident β1ARs or Oct3 prevent norepinephrine-dependent cardiac myocyte hypertrophy?
Does blockade of Golgi resident β1ARs or Oct3 prevent norepinephrine-dependent cardiac myocyte hypertrophy?
Golgi-localized β1-adrenergic receptors mediate norepinephrine-induced cardiac hypertrophy, revealing a novel intracellular pathway with implications for developing more efficacious β-blocker therapies.
Increased adrenergic tone resulting from cardiovascular stress leads to development of heart failure, in part, through chronic stimulation of β1 adrenergic receptors (βARs) on cardiac myocytes. Blocking these receptors is part of the basis for β-blocker therapy for heart failure. Recent data demonstrate that G protein-coupled receptors (GPCRs), including βARs, are activated intracellularly, although the biological significance is unclear. Here we investigated the functional role of Golgi βARs in cardiac myocytes and found they activate Golgi localized, prohypertrophic, phosphoinositide hydrolysis, that is not accessed by cell surface βAR stimulation. This pathway is accessed by the physiological neurotransmitter norepinephrine (NE) via an Oct3 organic cation transporter. Blockade of Oct3 or specific blockade of Golgi resident β1ARs prevents NE dependent cardiac myocyte hypertrophy. This clearly defines a physiological pathway activated by internal GPCRs in a biologically relevant cell type and has implications for development of more efficacious β-blocker therapies.
No takes yet. Share an insight, caveat, or question.
Nash et al. (2019) studied Cardiac hypertrophy. Blockade of Oct3 or Golgi resident β1ARs was evaluated on Norepinephrine-dependent cardiac myocyte hypertrophy. Blockade of Oct3 or specific blockade of Golgi resident β1ARs prevents norepinephrine-dependent cardiac myocyte hypertrophy, defining a physiological pathway activated by internal GPCRs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: